Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW Panel to Review Moderna’s RSV Jab, GSK’s ADC, and More on April 21
April 14, 2025
- Japan Govt Ends Subsidies for COVID Vaccinations from FY2025
April 14, 2025
- Scrap Coverage for OTC-Like Drugs with Same APIs and Dose as OTC Meds: Nippon Ishin
April 14, 2025
- Generic Dispensing Rates Spike on New LLP Coverage Rule: Survey
April 11, 2025
- 250 LDP Lawmakers Sign Petition for Revisiting Budget Cap, Off-Year Cuts
April 11, 2025
- MHLW on Alert for Potential Tariffs on Osteomalacia, Schizophrenia Meds
April 11, 2025
- Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
- Clinical Trial Matching Websites Do Not Violate Ad Regulations in PMD Act: MHLW
April 10, 2025
- MHLW Sets Up Task Force to Brace for US Tariffs
April 10, 2025
- Repeal of Off-Year Revision Means No Price Raise for Unprofitable Drugs: Minister
April 10, 2025
- Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
April 10, 2025
- Chuikyo OKs Discussion Timeline for FY2026 Reimbursement Reform
April 10, 2025
- Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
- Label Revisions Ordered for Xtandi, Paxlovid, and More Drugs
April 9, 2025
- Revise Regulations of Clinical Trial Info in PMD Act: Patient Advocate to Diet
April 9, 2025
- FPMAJ Renews Call for Scrapping Off-Year Drug Price Revision: Diet Hearing
April 9, 2025
- Japan Economic Minister Akazawa to Lead Tariff Talks with US
April 9, 2025
- PMDA Announces Guidance on “Competing Products” in Regulatory Review
April 8, 2025
- MHLW Now Soliciting Bids for FY2025 Budget Projects to Fight Drug Lag/Loss
April 8, 2025
- Ishiba, Trump Agree to Appoint Ministers for Tariffs Talks
April 8, 2025
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…